Myelodysplastic Syndromes: Developing Drug and Biological Products for Treatment: Draft Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 2, 2025
July 2, 2025
4c1a6b62-5c53-485e-9004-1b388e3f1bf3
Related Documents
Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology
Guidance DocumentJanuary 17, 2025Office of the Commissioner
Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment: Draft Guidance for Industry
Guidance DocumentAugust 17, 2020Office of the Commissioner
Osteoarthritis: Structural Endpoints for the Development of Drugs
Guidance DocumentAugust 23, 2018Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox